Iambic Therapeutics Plans Nasdaq IPO

Iambic Therapeutics filed for a proposed U.S. initial public offering on September 21, 2026, marking the latest move by an AI-focused biotech company to access public capital markets. The company intends to list its shares on the Nasdaq under the ticker symbol "IAM." The filing positions Iambic within a wave of life sciences businesses seeking to combine artificial intelligence with drug discovery and development.

The IPO documentation names J.P. Morgan, Jefferies, BofA Securities and Citigroup (C) as lead underwriters for the offering. Their roles will include managing the book-building process and coordinating the distribution of shares to institutional and other investors once the transaction proceeds. Specific terms of the offering, such as pricing and size, were not detailed in the available material.

Iambic’s shareholder base includes a group of prominent financial and strategic investors. Reported backers of the company include NVIDIA and the Qatar Investment Authority, alongside venture and growth equity firms such as Catalio, Nexus Ventures and Coatue Management. This mix of technology, sovereign wealth and venture capital support underscores the level of institutional interest in AI-driven approaches to drug discovery.

The presence of a large technology company among Iambic’s investors highlights a broader trend of crossover between advanced computing and life sciences. At the same time, participation from a sovereign wealth fund and specialist healthcare investors reflects an effort to pair long-term capital with higher-risk, innovation-focused biotech assets entering the public arena.

Iambic positions itself as a technology- and clinical-stage life sciences company that applies a proprietary AI-driven discovery platform to small-molecule drug development. Its operations center on integrating artificial intelligence with automated chemistry and biology workflows to advance therapeutic candidates. This model aims to streamline the identification and optimization of new small molecules for potential use in a range of disease areas.

As part of its strategy, Iambic has entered into a multi-year collaboration with AbbVie (ABBV). The partnership is focused on using Iambic’s AI-based platform to accelerate small-molecule drug discovery. Under the collaboration, Iambic’s technology and discovery capabilities are applied to programs of interest to AbbVie (ABBV), providing external validation of the platform’s relevance for large biopharmaceutical partners.

The combination of a planned Nasdaq listing, a syndicate of major global underwriters, backing from technology and institutional investors, and a multi-year collaboration with a large pharmaceutical company frames Iambic’s transition to the public markets. These elements define the company’s position as it seeks broader access to capital to further develop its AI-enabled small-molecule pipeline and external partnerships.